Table III.
Details of the two retrospective studies.
| First author | Study design | Cases, n (study duration) | Candidates | GroupingW | Regimen | Nutritional support | (Refs.) |
|---|---|---|---|---|---|---|---|
| Sun | Retrospective cohort study | 116 (January 2004 until June 2013) | AGC (stage II, III and IV included) with GOO | A: NAC + NS + OP, 62 cases | Folfox, mean 2.7 (1–4) cycles | (5) | |
| A1: NAC + EN + OP, 32 cases | Folfox, mean 3.1 cycles | EN: Fresubin Diabetesa or Nutrison Fibreb, 2,093–6,280 kJ/day via naso-jejunal tube or PEGJ, 40–85 days | |||||
| A2: NAC + PN + OP, 30 cases | Folfox, mean 1.5 cycles | PN: 104.7–125.6 kJ/kg•day, 20–35 days | |||||
| B: OP, 54 cases | |||||||
| Yamaguchi | Retrospective case series study | 13 (September 2001 until unknown date) | AGC (far advanced or non-curative respectable) with GOO | Single group | Paclitaxel + cisplatin + 5-FU, ≥2 cycles | Not disclosed | (4) |
a
Fresubin Diabetes produced by Sino-Swed Pharmaceutical Corp., Ltd.
b
Nutrison Fibre, produced by Nutricia. AGC, advanced gastric cancer; GOO, gastric outlet obstruction; NAC, neoadjuvant chemotherapy; NS, nutritional support; OP, operation; EN, enteral nutritional support; PN, parenteral nutritional support; PEGJ, percutaneous endoscopic gastrojejunostomy.